Thursday, April 02, 2020
Mind Medicine Inc., the leading neuro-pharmaceutical company for psychedelic inspired medicines, today announced the signing of a multi-year, branch exclusive collaboration with the laboratory of Professor Dr. Matthias Liechti, the world-leading psychedelics pharmacology and clinical research group at University Hospital Basel in Switzerland.
Under the agreement, MindMed gains exclusive worldwide rights to data, compounds, and patent rights associated with the Liechti laboratory's research with LSD and other psychedelic compounds, including data from preclinical studies and eight completed or ongoing LSD clinical trials. MindMed has already begun working with Professor Dr. Liechti's laboratory to file patents for the data and clinical trials it has generated over a 10-year period.
MindMed is particularly interested in the data and outcome of an ongoing placebo controlled Phase 2 trial of high dose LSD for the treatment of anxiety. The active arm of the Phase 2 trial is evaluating two single-dose administrations of LSD for the treatment of persons suffering from anxiety symptoms. MindMed is contemplating the creation of a drug development program using hallucinogenic doses of LSD for the treatment of anxiety disorders.
"It's a wonderful moment for our company to be recognized by Professor Dr. Liechti, the leading expert of LSD research in the world, as the right team to partner with in continuing our development of psychedelic inspired medicines," said MindMed Co-Founder & Co-CEO JR Rahn. "This exclusive partnership puts MindMed at the forefront of efforts to develop LSD and other psychedelics while also setting the tempo and caliber of our growing IP portfolio and clinical trial pipeline."
Basel, Switzerland is the birthplace of LSD and the University Hospital Basel, the world's leading center for LSD research, is led by Professor Dr. Matthias Liechti, a professor for clinical pharmacology and internal medicine at the University of Basel and an attending physician at the Division of Clinical Pharmacology and Toxicology of the University Hospital Basel where he also heads the psychopharmacology research group.
MindMed will support ongoing and planned clinical trials under the direction of Professor Dr. Liechti, including MindMed's planned micro-dosing study of LSD as a potential treatment for adult ADHD. Professor Dr. Liechti will have primary responsibility for development of the selected compounds, and MindMed will provide research funding and milestone payments in return for the exclusive license to existing and future data and IP generated from these clinical trials. The University Hospital Basel will receive royalties and development revenue on any products marketed through the collaboration.
"Over the past decade we have amassed the largest collection of clinical trials around LSD; we have been studying the pharmacology and potential medical uses of LSD and other psychedelics for many years in the laboratory, in patients, and in healthy volunteers," said Professor Dr. Liechti. "MindMed is the leading company with a similar mission to ours to use rigorous research and science to create mainstream medicines for neuro-psychiatric conditions. This collaboration now allows us to greatly accelerate our groundbreaking research."